Everolimus Efficacy Independent of Genetic Alterations in EGFR2-negative Breast Cancer

Share this content:
An exploratory analysis revealed that the efficacy of everolimus was independent of the most commonly altered genes in breast cancer.
An exploratory analysis revealed that the efficacy of everolimus was independent of the most commonly altered genes in breast cancer.

An exploratory analysis revealed that the efficacy of everolimus was independent of the most commonly altered genes or pathways in hormone-receptor positive human epidermal factor receptor 2-negative breast cancer, according to an article published online ahead of print in the Journal of Clinical Oncology.1

For this study, investigators sought to identify possible links between genetic alterations and efficacy of everolimus in patients enrolled in the BOLERO-2 trial. It had previously been established that the addition of everolimus to exemestane prolonged progression-free survival more than twofold in this patient population that had been previously treated with nonsteroidal aromatase inhibitors. 

To investigate correlations between the most common somatic alterations and degree of chromosomal instability, researchers used next-generation sequencing to analyze the genetic status of cancer-related genes in 302 archival tumor specimens.

Results showed that progression-free survival in patients who were treated with everolimus was maintained regardless of alteration status of PIK3CA, FGFR1, and CCND1.

RELATED: Accelerated Partial Breast Not Inferior to Whole-breast Irradiation Following Surgery

Patient subgroups—defined by the exon-specific mutations in PIK3CA or by different degrees of chromosomal instability in tumor tissues—experienced quantitative differences in everolimus benefit.

Investigators concluded that further study is needed to assess the impact of chromosomal instabilities and low-frequency generic alterations on everolimus efficacy.

Reference

  1. Hortobagyi GN, Chen D, Piccart M, et al. Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer: results from BOLERO-2 [published online ahead of print October 26, 2015]. J Clin Oncol. doi: 10.1200/JCO.2014.60.1971.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs